Prevention of cardiac mortality through antihypertensive therapy using a combination of angiotensin-converting enzyme inhibitors and beta-blockers: a retrospective cohort study in Tsunan, Japan

Antihypertensive treatment significantly reduces the risk of cardiovascular mortality in patients with hypertension; however, treatment effects are weaker on cardiac mortality than on cerebrovascular mortality, even with equivalent blood pressure reduction. A potential cause of this difference is the activation of neurohumoral factors; however, few studies have addressed this gap. Therefore, in this study, we evaluated the effectiveness of a combination therapy prioritizing angiotensin-converting enzyme inhibitors and beta-blockers in reducing cardiac mortality in outpatients with hypertension. The retrospective observational cohort study spanned 30 years (1987–2016) at a single institution. From 1992 to 2001, we prioritized the use of a combination of angiotensin-converting enzyme inhibitors and beta-blockers to suppress neurohumoral factors, with calcium channel blockers and diuretics used as supplementary treatments. We tracked the standardized mortality ratios for all-cause, cardiac, and cerebrovascular mortality during each period. Using national data, we retrospectively compared the trends in all-cause and cardiovascular mortality rates in our region with those of the Japanese population. The standardized mortality ratios for all-cause and cardiac mortality in our region decreased significantly from 1992 to 2016 (that is, after treatment initiation) and were significantly lower than national averages after the initial control period. These findings suggest that antihypertensive therapy prioritizing the combination of angiotensin-converting enzyme inhibitors and beta-blockers may contribute to a reduction in cardiac mortality. Future prospective, randomized, double-blind controlled trials are crucial for validating this hypothesis.